Enhertu® (Trastuzumab Deruxtecan) — Breakthrough ADC Redefining HER2-Targeted Cancer Treatment

The Most Active HER2-Targeted Therapy Ever Developed — Now Extending to HER2-Low and HER2-Mutant Cancers

Enhertu® (Trastuzumab Deruxtecan/T-DXd) is a HER2-targeted antibody-drug conjugate (ADC) consisting of three components — a HER2-targeting monoclonal antibody (Trastuzumab) linked via a novel tetrapeptide-based cleavable linker to a topoisomerase I inhibitor payload (DXd, an exatecan derivative) — at a high drug-to-antibody ratio (DAR) of approximately 8. This precisely engineered three-component ADC system delivers potent cytotoxic DXd payload selectively to HER2-expressing cancer cells — achieving unprecedented response rates and survival improvements in HER2-positive breast cancer, HER2-low breast cancer, HER2-positive gastric/GEJ adenocarcinoma, and HER2-mutant non-small cell lung cancer.

Enhertu has fundamentally transformed oncology practice in two ways — first by demonstrating the most active anti-tumour activity ever seen in HER2-positive metastatic breast cancer (median PFS 28.8 months in the DESTINY-Breast03 trial), and second by establishing an entirely new patient population — HER2-low breast cancer — as a treatable entity with HER2-directed therapy. The latter alone expanded the population eligible for HER2-targeted treatment from approximately 20% of metastatic breast cancer patients (HER2-positive) to approximately 60% (combining HER2-positive and HER2-low).

A.K. Pharma is a trusted medicine distributor in Delhi supplying genuine Enhertu (Trastuzumab Deruxtecan) to hospitals, oncology centres, breast cancer clinics, and pharmacies across India. Manufactured jointly by AstraZeneca and Daiichi Sankyo, Enhertu represents the leading edge of ADC technology and precision oncology — described by oncologists globally as one of the most important cancer medicines developed in the past decade.

What is Enhertu (Trastuzumab Deruxtecan)?

Enhertu contains Trastuzumab Deruxtecan — also known as T-DXd or DS-8201 — a third-generation HER2-targeted antibody-drug conjugate. Understanding its three-component architecture is essential to appreciating why it outperforms earlier HER2-targeted therapies:

Component 1 — HER2-Targeting Antibody (Trastuzumab): The antibody component is Trastuzumab — identical to the Trastuzumab (Herceptin) used in earlier HER2-targeted therapies. It binds with high affinity to the extracellular domain IV of HER2 — directing the ADC selectively to HER2-expressing cancer cells. The antibody also retains the direct anti-tumour mechanisms of Trastuzumab — ADCC activity, HER2 shedding inhibition, and PI3K/AKT pathway downregulation.

Component 2 — Cleavable Tetrapeptide Linker: A novel tetrapeptide linker (GGFG) connects the antibody to the DXd payload. This linker is specifically designed to be cleaved by lysosomal proteases (cathepsins) inside cancer cells after ADC internalisation — releasing the DXd payload intracellularly. The linker is stable in systemic circulation — minimising off-target DXd release and toxicity — but efficiently cleaved in the acidic, protease-rich lysosomal environment of tumour cells.

Component 3 — DXd Topoisomerase I Inhibitor Payload: DXd is a highly potent exatecan derivative that inhibits topoisomerase I — an enzyme essential for DNA replication and transcription. DXd is approximately 10 times more potent than the topoisomerase I inhibitor SN-38 (the active metabolite of irinotecan). Critically, DXd is membrane-permeable — allowing it to diffuse out of HER2-expressing cells after release and kill neighbouring tumour cells regardless of HER2 expression. This “bystander killing effect” is a key mechanism contributing to Enhertu’s activity in heterogeneous tumours including HER2-low cancers.

High Drug-to-Antibody Ratio (DAR ~8): Earlier ADCs like T-DM1 (Kadcyla) had a DAR of approximately 3.5 — meaning approximately 3-4 payload molecules per antibody. Enhertu has a DAR of approximately 8 — delivering approximately twice as much cytotoxic payload per antibody molecule. This higher payload density, combined with the more potent DXd payload and the bystander effect, explains Enhertu’s dramatically superior clinical activity compared to T-DM1.

Full prescribing information is available at the FDA label for Trastuzumab Deruxtecan.

Clinical Studies and Evidence

DESTINY-Breast03 Trial (T-DXd vs T-DM1 in HER2-Positive Metastatic Breast Cancer) Published in the New England Journal of Medicine (2022), DESTINY-Breast03 was a Phase 3 randomised controlled trial of 524 patients with HER2-positive unresectable or metastatic breast cancer who had received prior Trastuzumab and Taxane — the pivotal head-to-head comparison of Enhertu vs T-DM1 (Kadcyla) as second-line HER2-positive metastatic breast cancer therapy. Results at updated analysis:

• Progression-free survival — median PFS 28.8 months (Enhertu) vs 6.8 months (T-DM1) — HR 0.33 — an unprecedented 22-month PFS improvement never previously seen in HER2-positive metastatic breast cancer
• Overall survival — 12-month OS rate 94.1% (Enhertu) vs 85.9% (T-DM1); significantly improved OS at updated follow-up — HR 0.64
• Objective response rate — 79.7% (Enhertu) vs 34.2% (T-DM1) — more than double the response rate
• Complete response rate — 16.1% (Enhertu) vs 8.7% (T-DM1)
• Established Enhertu as the undisputed standard of care second-line HER2-positive metastatic breast cancer therapy — making T-DM1 clinically obsolete in this setting

The 28.8-month median PFS with Enhertu in second-line HER2-positive metastatic breast cancer is the longest PFS ever demonstrated in this setting — a result that transformed global treatment guidelines within months of publication.

DESTINY-Breast04 Trial (T-DXd in HER2-Low Metastatic Breast Cancer) Published in the New England Journal of Medicine (2022), DESTINY-Breast04 was a Phase 3 randomised controlled trial of 557 patients with HER2-low (IHC 1+ or IHC 2+/ISH–) metastatic breast cancer — a population previously considered HER2-negative and therefore ineligible for HER2-targeted therapy. Results:

• PFS — median PFS 9.9 months (Enhertu) vs 5.1 months (chemotherapy) in HR-positive patients — HR 0.50
• Overall survival — median OS 23.9 months (Enhertu) vs 17.5 months (chemotherapy) — HR 0.64 — significant OS benefit
• ORR — 52.6% (Enhertu) vs 16.3% (chemotherapy)
• Established HER2-low breast cancer as a new, distinct, and targetable entity — creating a new treatment indication and a new patient population estimated at 45-55% of all metastatic breast cancer patients
• This was widely described as one of the most practice-changing clinical trial results in oncology in 2022

DESTINY-Breast06 Trial (T-DXd in HER2-Ultralow Breast Cancer) The DESTINY-Breast06 trial extended Enhertu’s activity to HER2-ultralow breast cancer (IHC >0 but <1+) — further expanding the potential patient population for HER2-targeted therapy beyond HER2-low. Results demonstrated meaningful clinical activity in this previously undefined patient population — suggesting HER2 expression at any detectable level may be sufficient for Enhertu benefit.

DESTINY-Lung02 Trial (T-DXd in HER2-Mutant NSCLC) Published in the Journal of Clinical Oncology (2023), DESTINY-Lung02 demonstrated:

• ORR — 49.0% confirmed ORR in patients with HER2-mutant unresectable/metastatic NSCLC who had received prior platinum-based chemotherapy
• Median PFS — 9.9 months
• Duration of response — median DoR 11.3 months
• Established Enhertu as the first approved therapy specifically for HER2-mutant NSCLC — a biomarker-defined subset comprising approximately 2-4% of all NSCLC patients who had no previously approved targeted option
• HER2 mutations in NSCLC most commonly occur in exon 20 — predominantly in never-smokers and adenocarcinoma histology

DESTINY-Gastric01 Trial (T-DXd in HER2-Positive Gastric/GEJ Cancer) Published in the New England Journal of Medicine (2021), DESTINY-Gastric01 demonstrated:

• ORR — 51.3% (Enhertu) vs 14.3% (physician’s choice chemotherapy) — significantly higher
• Overall survival — median OS 12.5 months (Enhertu) vs 8.4 months (chemotherapy) — HR 0.59 — significantly improved
• Established Enhertu as effective and approved in HER2-positive gastric/GEJ adenocarcinoma after prior Trastuzumab-containing therapy
• First data demonstrating an ADC significantly improving OS in gastric cancer

DESTINY-Breast01 (T-DXd in Previously Treated HER2-Positive Breast Cancer) The Phase 2 DESTINY-Breast01 trial demonstrating 60.9% ORR in heavily pre-treated HER2-positive metastatic breast cancer patients — including patients who had received T-DM1 — was the initial proof-of-concept trial that established Enhertu’s remarkable activity and led to accelerated FDA approval.

Available Strengths

Enhertu is available as:

Dosing:

• 5.4mg/kg IV every 3 weeks (Q3W) — standard dose for all approved indications
• Administered as IV infusion:
  • First infusion: Over 90 minutes — observe for 90 minutes post-infusion for infusion reactions
  • Subsequent infusions: Over 30 minutes if first infusion tolerated — observe for 30 minutes post-infusion

Indications — What Enhertu is Used For

HER2-Positive Metastatic Breast Cancer:

• Unresectable or metastatic HER2-positive breast cancer in adults who have received a prior anti-HER2-based regimen — either in the metastatic setting or in the neo/adjuvant setting with recurrence within 6 months
• 5.4mg/kg Q3W — standard dose

HER2-Low Metastatic Breast Cancer:

• Unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH–) breast cancer in adults who have received prior chemotherapy in the metastatic setting or developed recurrence during or within 6 months of completing adjuvant chemotherapy
• HR-positive patients should have progressed on at least one endocrine therapy or be ineligible for endocrine therapy
• 5.4mg/kg Q3W — standard dose

HER2-Positive Gastric/GEJ Adenocarcinoma:

• Locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma in adults who have received a prior Trastuzumab-based regimen
• 6.4mg/kg Q3W — higher dose for gastric indication

HER2-Mutant NSCLC:

• Unresectable or metastatic NSCLC with activating HER2 (ERBB2) mutations in adults who have received prior platinum-based chemotherapy
• 5.4mg/kg Q3W — standard dose

For detailed indication information refer to MedlinePlus Trastuzumab Deruxtecan.

Key Benefits of Enhertu

Most Active HER2-Targeted Therapy in Oncology History The 28.8-month median PFS in DESTINY-Breast03 — more than quadrupling the PFS of T-DM1 — represents the most dramatic improvement ever seen in a head-to-head oncology trial in HER2-positive breast cancer. This result transformed Enhertu from a promising investigational agent to the undisputed standard of care in a single trial readout.

Established HER2-Low as a New Treatable Entity DESTINY-Breast04 created an entirely new cancer subtype — HER2-low breast cancer — that is now routinely tested for and targeted with Enhertu. This expanded the population eligible for HER2-targeted therapy from ~20% to ~60% of metastatic breast cancer patients — one of the most significant expansions of treatment eligibility in oncology.

Bystander Killing Effect — Activity in Heterogeneous Tumours Enhertu’s membrane-permeable DXd payload diffuses out of HER2-expressing cells after intracellular release — killing adjacent HER2-negative tumour cells. This bystander effect is particularly important in HER2-low cancers where HER2 expression is heterogeneous — ensuring tumour cells not directly targeted by the antibody are still affected.

High Drug-to-Antibody Ratio — Maximum Payload Delivery DAR ~8 delivers approximately twice the payload per antibody compared to T-DM1 (DAR ~3.5) — combined with the more potent DXd payload (10x more potent than SN-38) — resulting in dramatically greater cytotoxic effect per ADC molecule reaching the tumour.

Activity Across Multiple Tumour Types Proven activity in HER2-positive breast cancer, HER2-low breast cancer, HER2-positive gastric cancer, and HER2-mutant NSCLC — with ongoing trials in colorectal cancer, biliary tract cancer, endometrial cancer, and other HER2-expressing tumours. Enhertu is likely to receive additional indications as evidence matures.

First Approved Therapy for HER2-Mutant NSCLC Enhertu is the first and only approved targeted therapy for HER2-mutant NSCLC — a patient population with no previously approved targeted option despite HER2 mutation being a recognised oncogenic driver in this disease.

How Enhertu Works — ADC Mechanism in Detail

Step 1 — Systemic Circulation: After IV infusion, Enhertu circulates in the bloodstream as an intact ADC. The tetrapeptide linker is stable in plasma — minimising premature DXd release and reducing off-target toxicity.

Step 2 — HER2 Binding: The Trastuzumab antibody component binds with high affinity to HER2 domain IV on the surface of HER2-expressing cancer cells — including cells with high HER2 expression (IHC 3+, IHC 2+/ISH+) and low HER2 expression (IHC 1+, IHC 2+/ISH–).

Step 3 — Internalisation: The HER2-Enhertu complex is internalised into the cancer cell via receptor-mediated endocytosis — forming an endosome that fuses with lysosomes.

Step 4 — Lysosomal Cleavage: Lysosomal proteases (cathepsins B and L) cleave the tetrapeptide GGFG linker — releasing free DXd within the cancer cell.

Step 5 — Topoisomerase I Inhibition: Released DXd inhibits topoisomerase I — an enzyme that relieves torsional stress during DNA replication by creating transient single-strand DNA breaks. DXd stabilises the topoisomerase I-DNA cleavage complex — preventing religation of the DNA strand break → single and double strand DNA breaks accumulate → DNA damage response → cell cycle arrest → apoptosis.

Step 6 — Bystander Killing: Released DXd is membrane-permeable — it diffuses from the targeted HER2-expressing cell into surrounding tumour cells — killing HER2-negative or HER2-low neighbouring cells. This bystander effect is unique to Enhertu’s ADC design and is absent in T-DM1 (whose DM1 payload is membrane-impermeable).

Direct Antibody Effects: The Trastuzumab component also contributes directly — ADCC (antibody-dependent cellular cytotoxicity) activating NK cells to kill HER2-expressing cells, inhibition of HER2 ectodomain shedding, and downregulation of PI3K/AKT survival signalling — providing anti-tumour effects in addition to payload delivery.

For detailed mechanism overview refer to ESMO Breast Cancer Guidelines and ASCO Clinical Practice Guidelines.

HER2 Testing — Understanding HER2-Positive vs HER2-Low

HER2 status is determined by immunohistochemistry (IHC) and/or in situ hybridisation (ISH):

Key clinical implication: Pathologists must now distinguish between IHC 0 and IHC 1+ (and between IHC 1+ and IHC 2+/ISH–) — distinctions that were previously considered clinically irrelevant. Re-testing of archival samples may be warranted in patients previously classified as HER2-negative who may be HER2-low and eligible for Enhertu.

Enhertu vs T-DM1 (Kadcyla) — Why Enhertu is Superior

Dosage and Administration

Standard Dose — Breast Cancer and NSCLC:

• 5.4mg/kg IV every 3 weeks — based on actual body weight
• Maximum dose: 5.4mg/kg (do not use ideal body weight)

Gastric/GEJ Cancer:

• 6.4mg/kg IV every 3 weeks

Reconstitution:

• Reconstitute 100mg vial with 5mL sterile water for injection → 20mg/mL solution
• Calculate required volume, withdraw, and add to 100mL 5% Dextrose infusion bag
• Do NOT use sodium chloride (0.9% NaCl) — causes precipitation
• Use in-line 0.2 micron polyethersulfone filter during infusion

Infusion:

• First infusion: 90-minute IV infusion — observe patient for 90 minutes post-infusion
• Subsequent infusions: 30-minute IV infusion if previous infusions tolerated — observe 30 minutes post-infusion
• If infusion reaction occurs — slow infusion rate or interrupt; permanently discontinue for severe reactions

Dose Modifications for ILD:

• Grade 1 ILD — withhold Enhertu; restart only when completely resolved
• Grade 2 ILD — withhold; consider permanent discontinuation; restart at reduced dose (4.4mg/kg) only if resolved to Grade 0-1 within 28 days
• Grade 3-4 ILD — permanently discontinue — do not rechallenge

Dose Modifications for Other Toxicities:

• Dose reduction levels: 5.4mg/kg → 4.4mg/kg → 3.2mg/kg → permanently discontinue
• Refer to prescribing information for specific dose modification guidance per toxicity

Full dosing guidelines available at Drugs.com Trastuzumab Deruxtecan Dosage.

Critical Safety — Interstitial Lung Disease (ILD) and Pneumonitis

Enhertu carries a Black Box Warning for Interstitial Lung Disease (ILD) and Pneumonitis — the most important safety concern with this medicine:

• ILD/pneumonitis occurred in 10.5-15.4% of patients across DESTINY clinical trials — including fatal cases (Grade 5)
• Median time to ILD onset: approximately 5-6 months from first dose (range 0.7-27.5 months)
• ILD can occur at any time during treatment — vigilant monitoring throughout is essential

Monitoring:

• Baseline: chest CT scan or chest X-ray before starting Enhertu
• During treatment: monitor for new or worsening respiratory symptoms at every visit — cough, dyspnoea, fever, chest pain
• Any new pulmonary symptoms → prompt evaluation with CT scan

Management:

• Grade 1 (asymptomatic, radiological changes only) — withhold Enhertu; refer to pulmonologist; start systemic corticosteroids (prednisolone ≥0.5mg/kg/day) until improvement; restart only when completely resolved
• Grade 2 (symptomatic, limiting instrumental ADL) — withhold; start systemic corticosteroids; consider permanent discontinuation
• Grade 3-4 (severe symptoms, limiting self-care ADL, or life-threatening) — permanently discontinue; high-dose corticosteroids
• Do NOT restart Enhertu in patients who experienced Grade ≥3 ILD

Patient and Caregiver Education: All patients receiving Enhertu must be educated about ILD symptoms and instructed to contact their oncologist immediately if they develop new or worsening cough, shortness of breath, or fever.

Who Should Use Enhertu

Enhertu is prescribed for:

Breast Cancer:

• Adults with HER2-positive (IHC 3+ or IHC 2+/ISH+) unresectable or metastatic breast cancer after prior anti-HER2 therapy — standard second-line after Pertuzumab + Trastuzumab + Taxane
• Adults with HER2-low (IHC 1+ or IHC 2+/ISH–) unresectable or metastatic breast cancer after prior chemotherapy — HR-positive patients after endocrine therapy
• HER2 testing mandatory — IHC required; ISH for IHC 2+ tumours

Gastric/GEJ Cancer:

• Adults with HER2-positive (IHC 3+ or IHC 2+/ISH+) locally advanced or metastatic gastric or GEJ adenocarcinoma after prior Trastuzumab-based therapy
• HER2 testing mandatory — biopsy from most recent disease site preferred

NSCLC:

• Adults with unresectable or metastatic NSCLC with activating HER2 (ERBB2) mutations — exon 20 insertions most common — after prior platinum-based chemotherapy
• HER2 mutation testing mandatory — next-generation sequencing (NGS) recommended

Enhertu is prescribed by medical oncologists, breast cancer specialists, thoracic oncologists, and gastrointestinal oncologists. A.K. Pharma supplies Enhertu to hospitals, oncology centres, and pharmacies across Delhi and India.

Possible Side Effects

Common side effects include nausea (73-78%), fatigue (49-57%), vomiting (45-47%), alopecia (37-46%), constipation (34-38%), decreased appetite (29-32%), anaemia (27-31%), and neutropenia (23-30%).

Serious side effects include:

Interstitial Lung Disease (ILD) — Black Box Warning: As described above — occurs in 10-15% of patients including fatal cases. Vigilant monitoring and prompt management are essential. See ILD section above for complete management guidance.

Left Ventricular Dysfunction: Decreases in LVEF reported — monitor cardiac function with echocardiogram or MUGA scan before starting and periodically. Withhold for LVEF <40% or symptomatic congestive heart failure.

Embryo-Foetal Toxicity: Enhertu causes foetal harm based on mechanism. Effective contraception required during treatment and for 7 months (females) or 4 months (males) after final dose. Do not breastfeed during treatment and for 7 months after final dose.

Haematological Toxicity: Neutropenia, thrombocytopenia, and anaemia — monitor CBC before each cycle. Dose reduce or delay for Grade ≥3 haematological toxicity.

Full side effect information available at FDA Trastuzumab Deruxtecan Safety Information.

Precautions

• ILD monitoring — mandatory throughout treatment; patient education essential; prompt CT evaluation for any respiratory symptoms
• Cardiac function monitoring — LVEF assessment at baseline and every 3 months; withhold for significant decline
• HER2 testing — mandatory before prescribing; use most recent biopsy specimen; retesting of archival HER2-negative samples for HER2-low status may be warranted
• Neutropenia — CBC monitoring before each cycle; dose delay/reduction for Grade ≥3 neutropenia
• Drug reconstitution in 5% Dextrose ONLY — precipitation occurs with NaCl; do not use saline
• Pregnancy — teratogenic; effective contraception mandatory during and after treatment
• Breastfeeding — discontinue during treatment and for 7 months after final dose
• Infusion reactions — observe during and after each infusion; have resuscitation equipment available
• Refer to ESMO Breast Cancer Guidelines for complete management context

Storage and Handling

• Store in refrigerator between 2°C and 8°C
• Do not freeze
• Protect from light — keep in original carton
• Reconstituted solution: use within 24 hours at 2°C-8°C or within 4 hours at room temperature
• Diluted infusion solution: use within 24 hours at 2°C-8°C — do not freeze
• Single use vial — discard unused portion

As a responsible medicine distributor in Delhi, A.K. Pharma maintains full cold chain requirements during storage and supply of Enhertu ensuring product integrity for every unit supplied.

Manufacturer Information

Enhertu (Trastuzumab Deruxtecan) is jointly developed and commercialised by AstraZeneca and Daiichi Sankyo — a collaboration combining AstraZeneca’s oncology commercial expertise with Daiichi Sankyo’s pioneering ADC technology platform (DXd ADC platform). Trastuzumab Deruxtecan received FDA accelerated approval in December 2019 for HER2-positive breast cancer, with regular approval and expanded indications following DESTINY-Breast03, DESTINY-Breast04, DESTINY-Gastric01, and DESTINY-Lung02 results. A.K. Pharma supplies only genuine Enhertu sourced from authorized distributors.

Related Cancer Medicines Available at A.K. Pharma

• Imfinzi (Durvalumab) — anti-PD-L1 checkpoint inhibitor for lung cancer
• Tagrisso (Osimertinib) — EGFR inhibitor for EGFR-mutant NSCLC
• Faslodex (Fulvestrant) — SERD for HR-positive breast cancer
• Kryxana (Ribociclib) — CDK4/6 inhibitor for HR-positive breast cancer
• Browse all Cancer Medicines available at A.K. Pharma

Frequently Asked Questions

Q. What is Enhertu used for? Enhertu (Trastuzumab Deruxtecan) is used to treat HER2-positive and HER2-low metastatic breast cancer, HER2-positive gastric and gastroesophageal junction adenocarcinoma, and HER2-mutant non-small cell lung cancer. More information available at MedlinePlus.

Q. What is the generic name of Enhertu? The generic name of Enhertu is Trastuzumab Deruxtecan — also referred to as T-DXd or DS-8201. It is a HER2-targeted antibody-drug conjugate jointly developed by AstraZeneca and Daiichi Sankyo.

Q. What is HER2-low breast cancer and why is it important? HER2-low breast cancer is defined as IHC 1+ or IHC 2+/ISH– HER2 expression — previously classified as HER2-negative. The DESTINY-Breast04 trial established that Enhertu significantly improves progression-free and overall survival in HER2-low metastatic breast cancer — creating an entirely new treatable patient population. Approximately 45-55% of metastatic breast cancer patients are HER2-low — dramatically expanding the number of patients eligible for Enhertu.

Q. How is Enhertu different from Kadcyla (T-DM1)? Enhertu has a higher drug-to-antibody ratio (~8 vs ~3.5), uses a more potent topoisomerase I inhibitor payload (DXd — 10x more potent than SN-38), has a cleavable linker enabling intracellular payload release, and has a membrane-permeable payload enabling bystander killing of HER2-negative neighbouring cells. The DESTINY-Breast03 trial demonstrated a 28.8-month median PFS with Enhertu vs 6.8 months with T-DM1 — establishing Enhertu as markedly superior.

Q. What is ILD and why is it a concern with Enhertu? ILD (Interstitial Lung Disease) is inflammation and scarring of lung tissue — a serious and potentially fatal side effect of Enhertu occurring in approximately 10-15% of patients. It carries a Black Box Warning. Patients must be monitored throughout treatment for new or worsening respiratory symptoms (cough, breathlessness, fever). Any new respiratory symptoms require immediate CT scan evaluation. Grade ≥3 ILD requires permanent discontinuation.

Q. What dose of Enhertu is used for breast cancer vs gastric cancer? For breast cancer and NSCLC the dose is 5.4mg/kg IV every 3 weeks. For gastric/GEJ adenocarcinoma the dose is 6.4mg/kg IV every 3 weeks. Both doses are based on actual body weight.

Q. Can Enhertu be diluted in normal saline? No — Enhertu must only be diluted in 5% Dextrose solution. Precipitation occurs with sodium chloride (normal saline or 0.9% NaCl) — which is a critical preparation error to avoid. Always use a 5% Dextrose infusion bag.

Q. Is Enhertu available in India? Enhertu can be supplied to hospitals, oncology centres, and pharmacies across India through licensed pharmaceutical distributors. Contact A.K. Pharma — medicine distributor in Delhi — for availability and pricing.

Q. What is the price of Enhertu in India? Enhertu 100mg price in India varies. Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for current pricing and bulk supply rates.

Q. How to order Enhertu from A.K. Pharma? You can request a quote directly from this page, call us at 011 4172 6999, or WhatsApp us at +91 9810034827 with your requirements and we will respond promptly.

Q. Does A.K. Pharma supply Enhertu in bulk? Yes. A.K. Pharma supplies Enhertu in bulk to oncology centres, breast cancer clinics, hospitals, and pharmacies across Delhi and India. Contact us for bulk pricing and availability.

Why Order Enhertu from A.K. Pharma?

• Licensed medicine distributor in Delhi with all required drug licenses
• 100% genuine Enhertu sourced from authorized AstraZeneca/Daiichi Sankyo distributors
• Cold chain maintained throughout storage and delivery
• Available alongside companion breast cancer and lung cancer medicines — simplifying oncology procurement
• Bulk supply available for hospitals and oncology centres
• Prompt response to all quote requests
• Serving oncologists and breast cancer specialists across Delhi NCR and India

Contact A.K. Pharma for Enhertu Supply 📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052 📞 011 4172 6999 📱 WhatsApp: +91 9810034827 🌐 akpharma.in